Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Imclone systems (IMCL) -- Ignore unavailable to you. Want to Upgrade?

To: CPAMarty who wrote (555)	3/30/1999 11:55:00 PM
From: 5,17,37,5,101,...	Read Replies (1) \| Respond to of 2515

I was just reading Cruttenden Roth report on IMCL dated Q1/98 Target price: $16 for the end of 1999 based on DCF (so I assume it may be a couple bucks higher now because approval is a year closer and Merck deal probably better than expected.) Approval of C225 expected mid2001 Around mid99 we should expect results from C225 renal cell PII and a IND filing for antiangiogenesis drug which is expected to be early in its class (ie frontrunner) This info available from local library. JAckson